Company Filing History:
Years Active: 2024
Title: Innovations of Jonathan Hogan in Chimeric Autoantibody Receptor T Cells
Introduction
Jonathan Hogan is an accomplished inventor based in Haddonfield, NJ (US). He has made significant contributions to the field of immunology through his innovative work on chimeric autoantibody receptor T cells. His research focuses on developing novel therapeutic approaches for autoimmune diseases.
Latest Patents
Jonathan Hogan holds a patent for "Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cells." This invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor. The patent also covers polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant T cells that express the CAAR. Additionally, the invention outlines methods for creating genetically modified cells, such as T cells, that express a PLA2R-CAAR, which includes a PLA2R extracellular domain.
Career Highlights
Jonathan Hogan is affiliated with the University of Pennsylvania, where he continues to advance his research in the field of immunotherapy. His work has the potential to impact the treatment of various autoimmune conditions, showcasing his dedication to improving patient outcomes through innovative science.
Collaborations
Some of his notable coworkers include Saar Gill and Aimee S Payne, who contribute to the collaborative efforts in his research endeavors.
Conclusion
Jonathan Hogan's innovative work in the development of chimeric autoantibody receptor T cells represents a significant advancement in immunology. His contributions are paving the way for new therapeutic strategies in the treatment of autoimmune diseases.